CHICAGO (EGMN) - The novel cytokine interleukin-21 has shown itself to be biologically active with an overall response rate of 22% in first-line metastatic melanoma patients. Median progression-free survival reached 4.32 months in the phase II, multicenter IND 189 trial involving 40 patients, Dr. Teresa Petrella reported on behalf of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).This finding held up well when it was benchmarked against the widely cited Korn meta-analysis...